These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 36300259)

  • 1. Are inhaled mRNA vaccines safe and effective? A review of preclinical studies.
    Jansen EM; Frijlink HW; Hinrichs WL; Ruigrok MJ
    Expert Opin Drug Deliv; 2022 Nov; 19(11):1471-1485. PubMed ID: 36300259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19.
    Heida R; Hinrichs WL; Frijlink HW
    Expert Rev Vaccines; 2022 Jul; 21(7):957-974. PubMed ID: 33749491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
    Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
    Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonclinical Safety Assessment of Lipid Nanoparticle-and Emulsion-Based Self-Amplifying mRNA Vaccines in Rats.
    Donahue DA; Ballesteros C; Maruggi G; Glover C; Ringenberg MA; Marquis M; Ben Abdeljelil N; Ashraf A; Rodriguez LA; Stokes AH
    Int J Toxicol; 2023; 42(1):37-49. PubMed ID: 36472205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
    Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE
    Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Making COVID-19 mRNA vaccines accessible: challenges resolved.
    Niazi SK
    Expert Rev Vaccines; 2022 Sep; 21(9):1163-1176. PubMed ID: 35695469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses.
    Almendro-Vázquez P; Chivite-Lacaba M; Utrero-Rico A; González-Cuadrado C; Laguna-Goya R; Moreno-Batanero M; Sánchez-Paz L; Luczkowiak J; Labiod N; Folgueira MD; Delgado R; Paz-Artal E
    Front Immunol; 2022; 13():981350. PubMed ID: 36059485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
    Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
    Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.
    van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP
    Front Immunol; 2021; 12():781280. PubMed ID: 34987509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
    Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y
    Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models.
    Banihashemi SR; Es-Haghi A; Fallah Mehrabadi MH; Nofeli M; Mokarram AR; Ranjbar A; Salman M; Hajimoradi M; Razaz SH; Taghdiri M; Bagheri M; Dadar M; Hassan ZM; Eslampanah M; Salehi Najafabadi Z; Lotfi M; Khorasani A; Rahmani F
    Front Immunol; 2022; 13():836745. PubMed ID: 35693788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models.
    Maruggi G; Mallett CP; Westerbeck JW; Chen T; Lofano G; Friedrich K; Qu L; Sun JT; McAuliffe J; Kanitkar A; Arrildt KT; Wang KF; McBee I; McCoy D; Terry R; Rowles A; Abrahim MA; Ringenberg MA; Gains MJ; Spickler C; Xie X; Zou J; Shi PY; Dutt T; Henao-Tamayo M; Ragan I; Bowen RA; Johnson R; Nuti S; Luisi K; Ulmer JB; Steff AM; Jalah R; Bertholet S; Stokes AH; Yu D
    Mol Ther; 2022 May; 30(5):1897-1912. PubMed ID: 34990810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells.
    Bevers S; Kooijmans SAA; Van de Velde E; Evers MJW; Seghers S; Gitz-Francois JJJM; van Kronenburg NCH; Fens MHAM; Mastrobattista E; Hassler L; Sork H; Lehto T; Ahmed KE; El Andaloussi S; Fiedler K; Breckpot K; Maes M; Van Hoorick D; Bastogne T; Schiffelers RM; De Koker S
    Mol Ther; 2022 Sep; 30(9):3078-3094. PubMed ID: 35821637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expert review on global real-world vaccine effectiveness against SARS-CoV-2.
    Chuenkitmongkol S; Solante R; Burhan E; Chariyalertsak S; Chiu NC; Do-Van D; Husin M; Hwang KP; Kiertiburanakul S; Kulkarni PS; Lee PI; Lobo RC; Nghia CH; Ong-Lim A; Sivasampu S; Suah JL; Tok PSK; Thwaites G;
    Expert Rev Vaccines; 2022 Sep; 21(9):1255-1268. PubMed ID: 35748494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.